Roche aims to ‘underwhelm’ on SMA drug price to challenge rivals
Spinraza's list price is $750,000 in the first year, and $375,000 thereafter, while Novartis's gene therapy for the genetic muscle…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Fitch ratings
Proposed cap on trade margins will not hurt pharma cos
Citing media reports Fitch said, the National Pharmaceutical Pricing Authority is making progress in reaching a consensus with…